Plasma Proteome Profiling Reveals Inflammation Markers and Tafamidis Effects in V30M Transthyretin Polyneuropathy
International Journal of Molecular Sciences · 10.06.2025 · 26 (12) · 5534
DOI: 10.3390/ijms26125534 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.06.2025. Verfasst von Karina Nugroho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA. Hauptthemen laut MEDLINE: Prealbumin, Amyloid Neuropathies, Familial, Proteome, Benzoxazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, American Heart Association, Ellen Browning Scripps Foundation.
Abstract (Originalsprache)
Transthyretin (TTR) variant (V30M) polyneuropathy (ATTRv-PN) is a progressive systemic amyloidosis caused by transthyretin aggregation, leading to a variety of debilitating manifestations, including neuropathy and cardiomyopathy. We investigated the plasma proteome of heterozygotic V30M TTR asymptomatic carriers and heterozygotic V30M ATTRv-PN patients (before and after tafamidis treatment) versus WT TTR healthy control plasma using an organic solvent-induced shift in solubility assay to identify biosignatures for disease progression and therapeutic response. We identified many proteins, including TTR, apolipoproteins, ceruloplasmin, and proteins with functions in innate immunity that displayed changes in either their abundances or their sensitivity to precipitation. Elevated oxidative modifications of TTR and APOE in ATTRv-PN patients suggest a role for oxidative stress in disease pathogenesis/progression. Tafamidis treatment mitigated these pathology-associated changes, suggesting that alleviating proteotoxic stress impacts these other pathways. Although our study was limited to a Portuguese cohort, these findings nevertheless provide a comprehensive plasma proteomic profile of V30M ATTRv-PN patients, V30M TTR carriers, and tafamidis-treated ATTRv-PN patients over up to 60 months; provide insights into ATTRv-PN pathophysiology; identify potential biomarkers for disease progression and therapeutic response; and highlight the utility of proteomics in advancing personalized treatments for amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
- Centro Hospitalar Universitário Santo António, 4050-342 Porto, Portugal.
- Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
- The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
ORCID-Profile: Karina Nugroho, James J Moresco, Antonio F M Pinto, Evan T Powers
Förderung
- NIDDK NIH HHS
- American Heart Association
- Ellen Browning Scripps Foundation
- National Institutes of Health
- American Heart Association Predoctoral fellowship and Ellen Browning Scripps Foundation
Zitieren
APA
Nugroho, K., Lin, C. Y., Monteiro, C., Coelho, T., Moresco, J. J., Pinto, A. F. M., Powers, E. T., Yates, J. R., Diedrich, J. K., & Kelly, J. W. (2025). Plasma Proteome Profiling Reveals Inflammation Markers and Tafamidis Effects in V30M Transthyretin Polyneuropathy. International Journal of Molecular Sciences, 26(12), 5534. https://doi.org/10.3390/ijms26125534
Vancouver
Nugroho K, Lin CY, Monteiro C, Coelho T, Moresco JJ, Pinto AFM, et al. Plasma Proteome Profiling Reveals Inflammation Markers and Tafamidis Effects in V30M Transthyretin Polyneuropathy. International Journal of Molecular Sciences. 2025;26(12):5534. doi:10.3390/ijms26125534
BibTeX
@article{Nugroho2025,
author = {Nugroho, Karina and Lin, Chung-Yon and Monteiro, Cecilia and Coelho, Teresa and Moresco, James J and Pinto, Antonio F M and Powers, Evan T and Yates, John R and Diedrich, Jolene K and Kelly, Jeffery W},
title = {Plasma Proteome Profiling Reveals Inflammation Markers and Tafamidis Effects in V30M Transthyretin Polyneuropathy},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {12},
pages = {5534},
doi = {10.3390/ijms26125534}
}
EUVIMED